For those of you who are old enough to remember the 1970s, you may remember waiting in long lines to get vaccinated against the swine flu that was sweeping the nation at that time … likely because you were alerted by television PSAs such as this one:
 
In case you were wondering, this is not the same swine flu of three-plus decades ago, according to MSNBC. If you had that vaccine – or even your annual flu shot just months ago – you should not consider yourself immune. Check the MSNBC story for for more FAQs on the swine flu. 
Video & …read more

BioCurex is a cancer research and development company that has developed a method of cancer detection surpassing others in the field with the use of their patented RECAF™ technology.
With the said test, scientists at BioCurex can differentiate cancer cells from healthy cells in ways that previous scientists have been unable to do.
According to Dr. Moro-Vidal, BioCurex’s President and CEO:
“Cancer markers help distinguish cancer cells from non-cancerous cells. The ideal marker is a molecule that’s present in all cancer cells of all tissue types — none of the present markers can do that; and RECAF is the only one discovered to …read more

A research group headed by James Morre, Ph.D., professor of medicinal chemistry at Purdue University, obtained results supporting that phenoxodiol (an investigational drug) may be effective in the treatment of prostate cancer by specifically targeting a protein on prostate cancer cells known as tNOX 75 alpha.
The Purdue team has identified the protein, tumor-associated NADH oxidase (or tNOX), as a pan-cancer marker. The protein is critical to the ability of the tumor cell to grow and to survive.
They also have shown that there are different forms of this protein, known as isoforms, and that different tNOX isoforms are associated with different …read more